Bank of Hawaii Sells 2,288 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Bank of Hawaii cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,681 shares of the biopharmaceutical company’s stock after selling 2,288 shares during the quarter. Bank of Hawaii’s holdings in Gilead Sciences were worth $2,966,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Pin Oak Investment Advisors Inc. bought a new position in Gilead Sciences in the 4th quarter worth $26,000. Baldwin Brothers Inc. MA lifted its position in shares of Gilead Sciences by 63.3% in the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 136 shares in the last quarter. IndexIQ Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $28,000. Engrave Wealth Partners LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $29,000. Finally, Tortoise Investment Management LLC raised its stake in Gilead Sciences by 922.2% during the 4th quarter. Tortoise Investment Management LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 415 shares during the period. 80.15% of the stock is owned by institutional investors.
A number of equities research analysts have issued reports on the stock. HC Wainwright lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating in a report on Monday, March 2nd. Credit Suisse Group reiterated a “sell” rating and issued a $60.00 price target on shares of Gilead Sciences in a report on Friday, April 17th. BMO Capital Markets cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 price target on the stock. in a research note on Monday, April 20th. Sanford C. Bernstein lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $78.00 to $70.00 in a research report on Thursday, February 6th. Finally, Cantor Fitzgerald boosted their target price on Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 7th. Five research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $79.31.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.11. The firm had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The business’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.67 earnings per share. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 6.39 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Friday, June 12th will be paid a $0.68 dividend. The ex-dividend date of this dividend is Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a yield of 3.54%. Gilead Sciences’s dividend payout ratio is currently 44.30%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares in the company, valued at approximately $2,155,372.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $67.26, for a total transaction of $162,298.38. Following the transaction, the director now directly owns 57,273 shares in the company, valued at approximately $3,852,181.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,144 shares of company stock worth $3,931,225. Corporate insiders own 0.13% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: What is the CAC 40 Index?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.